Method and Composition to Evaluate Cytochrome P450 2D6 Isoenzyme Activity Using a Breath Test
    1.
    发明申请
    Method and Composition to Evaluate Cytochrome P450 2D6 Isoenzyme Activity Using a Breath Test 审中-公开
    使用呼吸试验评估细胞色素P450 2D6同工酶活性的方法和组成

    公开(公告)号:US20100329979A1

    公开(公告)日:2010-12-30

    申请号:US12874350

    申请日:2010-09-02

    IPC分类号: A61K51/08

    CPC分类号: C12Q1/26 A61K51/1206

    摘要: The present invention relates, generally to a method of determining and assessing cytochrome P450 2D6 isoenzyme (CYP2D6)-related metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by a the subject upon intravenous or oral administration of a 13C-labeled CYP2D6 substrate compound. The present invention is useful as an in vivo phenotype assay for evaluating CYP2D6-related activity using the metabolite 13CO2 in expired breath and to determine the optimal dosage and timing of administration of CYP2D6 substrate compound.

    摘要翻译: 本发明一般涉及通过呼吸测定法确定和评估个体哺乳动物受试者中的细胞色素P450 2D6同工酶(CYP2D6)相关代谢能力的方法,通过确定受试者在静脉内或口服时呼出的13CO2的相对量 施用13C标记的CYP2D6底物化合物。 本发明可用作体内表型测定法,用于使用呼气中的代谢物13CO2评估CYP2D6相关活性,并确定CYP2D6底物化合物的最佳剂量和给药时间。

    METHODS TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST
    2.
    发明申请
    METHODS TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST 审中-公开
    评估细胞色素P450 2C19使用呼吸试验的ISOENZYME活性的方法

    公开(公告)号:US20110111510A1

    公开(公告)日:2011-05-12

    申请号:US12942280

    申请日:2010-11-09

    IPC分类号: G01N37/00 C07D401/12

    摘要: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2C19) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The present invention is useful as anon-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite 13CO2 in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.

    摘要翻译: 本发明一般涉及通过呼吸测定法确定个体哺乳动物受试者的细胞色素P450 2C19相关(CYP2C19)代谢能力的方法,通过确定受试者在静脉内或口服给药后呼出的13CO2的相对量 13C标记的CYP2C19底物化合物。 本发明可用作用于评估受试者中使用呼吸道呼吸中代谢物13CO2的CYP2C19酶活性的非侵入式体内测定,以表现个体受试者并确定药物施用的选择,最佳剂量和时间。

    Methods to evaluate cytochrome P450 2C19 isoenzyme activity using a breath test
    3.
    发明授权
    Methods to evaluate cytochrome P450 2C19 isoenzyme activity using a breath test 有权
    使用呼吸试验评估细胞色素P450 2C19同工酶活性的方法

    公开(公告)号:US07833744B2

    公开(公告)日:2010-11-16

    申请号:US11848750

    申请日:2007-08-31

    IPC分类号: C12Q1/26

    摘要: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite 13CO2 in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.

    摘要翻译: 本发明一般涉及通过呼吸测定法确定和评估个体哺乳动物受试者中细胞色素P450 2C19相关(CYP2Cl9)代谢能力的方法,通过确定受试者在静脉内或口服给药后呼出的13CO2的相对量 13C标记的CYP2C19底物化合物。 本发明可用作非侵入性体内测定,用于评估受试者中使用呼吸道呼吸中的代谢物13CO2,表型个体受试者的CYP2C19酶活性,并确定药物给药的选择,最佳剂量和时机。

    METHOD AND COMPOSITION TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST
    4.
    发明申请
    METHOD AND COMPOSITION TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST 有权
    评估细胞色素P450 2C19的方法和组合使用通气测试的ISOENZYME活性

    公开(公告)号:US20080085240A1

    公开(公告)日:2008-04-10

    申请号:US11848750

    申请日:2007-08-31

    IPC分类号: A61K51/04 G01N33/00

    摘要: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite 13CO2 in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.

    摘要翻译: 本发明一般涉及通过呼吸测定法确定和评估个体哺乳动物受试者中细胞色素P450 2C19相关(CYP2Cl9)代谢能力的方法,通过确定相对量 静脉内或口服施用13 C- C标记的CYP2C19底物化合物时,受试者呼出的> 2 。 本发明可用作非侵入式体内测定,用于使用呼吸道呼吸中的代谢物13评价受试者中CYP2C19酶活性,以表现个体受试者 并确定药物给药的选择,最佳剂量和时间。

    Reagent and method for measuring lung function
    5.
    发明授权
    Reagent and method for measuring lung function 失效
    用于测量肺功能的试剂和方法

    公开(公告)号:US06890305B2

    公开(公告)日:2005-05-10

    申请号:US10372982

    申请日:2003-02-26

    摘要: The present invention relates to an assay for evaluating alveolar exchange of oxygen. A 13C-labeled substrate, such as 13C-sodium bicarbonate is administered to a subject by oral or iv intake, and exhaled 13CO2 is measured. The 13CO2 in expired breath can be collected at various time points following administration of the substrate and measured in Δ per mil with a mass analyzer or photometer, such as an IR spectrometer. This process can be used as a diagnostic test for the indication of, treatment and/or evaluation of the severity of respiratory tract diseases or infections.

    摘要翻译: 本发明涉及评估氧气的肺泡交换的测定。 通过口服或静脉内摄入向受试者施用13 C-标记的底物,例如13 C-碳酸氢钠,并呼出了13C 测量<2> 。 通气呼吸中的第13个CO 2 2可以在施用基底后的各个时间点收集,并用质量分析仪或光度计(例如IR 光谱仪 该过程可用作对呼吸道疾病或感染的严重程度的指示,治疗和/或评估的诊断测试。

    RNA hydrolysis
    6.
    发明授权
    RNA hydrolysis 失效
    RNA水解

    公开(公告)号:US06258941B1

    公开(公告)日:2001-07-10

    申请号:US07947071

    申请日:1992-09-16

    IPC分类号: C07H2100

    CPC分类号: C07H23/00

    摘要: The selected sequence-directed hydrolysis of RNA under physiologically relevant conditions is described using conjugates comprising metal complexes covalently linked to oligodeoxynucleotides as hydrolysis agents. The oligodeoxynucleotide portions of the agents are selected to provide molecular recognition via the Watson Crick base pairing to the target RNA sequence to be hydrolyzed. A method is described for determining the RNA hydrolysis effectiveness of metals and ligands used to form the metal complexes useful in this invention.

    摘要翻译: 使用包含与寡脱氧核苷酸共价连接的金属络合物作为水解剂的缀合物描述了在生理学相关条件下所选择的RNA的顺序定向水解。 选择试剂的寡脱氧核苷酸部分以通过与待水解的靶RNA序列配对的Watson Crick碱提供分子识别。 描述了一种用于确定用于形成本发明中有用的金属络合物的金属和配体的RNA水解效力的方法。